Elisabet Svenungsson

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8806705/elisabet-svenungsson-publications-by-year.pdf
Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163 papers	6,000 citations	38 h-index	74 g-index
190 ext. papers	7,939 ext. citations	4.7 avg, IF	5.53 L-index

#	Paper	IF	Citations
163	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. *Annals of the Rheumatic Diseases*, **2022**,	2.4	6
162	Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus.. *Lupus Science and Medicine*, **2022**, 9,	4.6	0
161	Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations. *ACR Open Rheumatology*, **2021**,	3.5	2
160	Factors associated with self-reported capacity to walk, jog and run in individuals with systemic lupus erythematosus. *Archives of Rheumatology*, **2021**, 36, 89-100	0.9	
159	Interaction between the rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2021**, 80, 1183-1189	2.4	1
158	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. *Lupus Science and Medicine*, **2021**, 8,	4.6	4
157	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. *Arthritis Research and Therapy*, **2021**, 23, 132	5.7	4
156	Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. *Lupus*, **2021**, 30, 1289-1299	2.6	1
155	AB0318 RISK FOR CONCOMITANT AUTOIMMUNITY IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME; A SWEDISH COHORT STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 1184.1-1184	2.4	
154	POS0764 EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION. *Annals of the Rheumatic Diseases*, **2021**, 80, 635.2-636	2.4	
153	POS0184 URINE-GALECTINE 3 BINDING PROTEIN (U-GAL3BP) IS A SENSITIVE MARKER OF KIDNEY INFLAMMATION AND RESPONSE TO TREATMENT IN LUPUS. *Annals of the Rheumatic Diseases*, **2021**, 80, 305.2-306	2.4	
152	POS1425 ANTIBODIES TO PORPHYROMONAS GINGIVALIS ASSOCIATE WITH THE PRESENCE OF RHEUMATOID ARTHRITIS-RELATED AUTOANTIBODIES IN PATIENTS WITH PERIODONTITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 996.1-996	2.4	0
151	A Comprehensive Evaluation of the Relationship Between Different IgG and IgA Anti-Modified Protein Autoantibodies in Rheumatoid Arthritis. *Frontiers in Immunology*, **2021**, 12, 627986	8.4	5
150	POS0009 THE RELATIONSHIP BETWEEN DIFFERENT IGG AND IGA ANTI-MODIFIED PROTEIN AUTOANTIBODIES IN RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 206.1-207	2.4	
149	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. *Annals of the Rheumatic Diseases*, **2021**, 80, 1175-1182	2.4	2
148	Variants in BANK1 are associated with lupus nephritis of European ancestry. *Genes and Immunity*, **2021**, 22, 194-202	4.4	2
147	Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. *Lupus Science and Medicine*, **2021**, 8,	4.6	1

146	Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes. *Arthritis Care and Research*, **2021**, 73, 574-579	4.7	2
145	Contributions of de novo variants to systemic lupus erythematosus. *European Journal of Human Genetics*, **2021**, 29, 184-193	5.3	2
144	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. *Rheumatology*, **2021**, 60, 1445-1455	3.9	1
143	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. *Annals of the Rheumatic Diseases*, **2021**, 80, 109-117	2.4	10
142	The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies. *Thrombosis and Haemostasis*, **2021**, 121, 1299-1309	7	0
141	DNA Methylation-Based Interferon Scores Associate With Sub-Phenotypes in Primary Sjögren's Syndrome. *Frontiers in Immunology*, **2021**, 12, 702037	8.4	4
140	Global epidemiology of systemic lupus erythematosus. *Nature Reviews Rheumatology*, **2021**, 17, 515-532	8.1	29
139	Infection hospitalisation in systemic lupus in Sweden. *Lupus Science and Medicine*, **2021**, 8,	4.6	2
138	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. *Lupus Science and Medicine*, **2021**, 8,	4.6	5
137	Could severe COVID-19 be considered a complementopathy?. *Lupus Science and Medicine*, **2020**, 7,	4.6	3
136	Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?. *Diabetes and Vascular Disease Research*, **2020**, 17, 1479164120922123	3.3	1
135	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1387-1393	5.3	6
134	Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-β glycoprotein I domain 1 antibodies. *Lupus*, **2020**, 29, 463-473	2.6	6
133	The binding of SLE autoantibodies to mitochondria. *Clinical Immunology*, **2020**, 212, 108349	9	6
132	The antiphospholipid syndrome - often overlooked cause of vascular occlusions?. *Journal of Internal Medicine*, **2020**, 287, 349-372	10.8	14
131	Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. *Rheumatology*, **2020**, 59, 3264-3274	3.9	7
130	Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. *Journal of Rheumatology*, **2020**, 47, 865-875	4.1	13
129	OP0101-HPR QUALITY OF LIFE IN PEOPLE WITH SYSTEMIC SCLEROSIS WITH DIFFERENT DEGREES OF LUNG DISEASE - A CROSS-SECTIONAL STUDY. *Annals of the Rheumatic Diseases*, **2020**, 79, 66.3-66	2.4	

128	AB0127 ACCUMULATION OF ANTI-NUCLEAR ASSOCIATED AUTOANTIBODIES IN CIRCULATING IMMUNE COMPLEXES IS MORE PROMINENT IN SLE PATIENTS FROM SUDAN COMPARED TO SWEDEN. *Annals of the Rheumatic Diseases*, **2020**, 79, 1364-1365	2.4	
127	THU0224 SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS. *Annals of the Rheumatic Diseases*, **2020**, 79, 339.2-339	2.4	
126	SAT0204 COMPARING OCCURRENCE AND CLINICAL SIGNIFICANCE OF ANTI-PHOSPHOLIPID AUTOANTIBODIES AMONG SUDANESE AND SWEDISH SLE PATIENTS USING CONVENTIONAL AND NATION-BASED CUTOFFS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1044.2-1045	2.4	
125	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2020**, 79, 254-261	2.4	18
124	Epilepsy in systemic lupus erythematosus: prevalence and risk factors. *European Journal of Neurology*, **2020**, 27, 297-307	6	9
123	ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. *Rheumatology*, **2020**, 59, 2237-2249	3.9	15
122	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2020**, 79, 363-369	2.4	39
121	High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. *Lupus*, **2020**, 29, 1412-1422	2.6	3
120	Accumulation of antinuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden. *Scientific Reports*, **2020**, 10, 21126	4.9	3
119	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis and Rheumatology*, **2020**, 72, 67-77	9.5	18
118	Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. *Rheumatology*, **2020**, 59, 968-978	3.9	10
117	Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511. *Diabetes Care*, **2020**, 43, e9	14.6	
116	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. *Annals of the Rheumatic Diseases*, **2020**,	2.4	2
115	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. *Human Genetics*, **2019**, 138, 141-150	6.3	32
114	Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. *Diabetes Care*, **2019**, 42, 1504-1511	14.6	8
113	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. *Frontiers in Immunology*, **2019**, 10, 1029	8.4	8
112	Microparticles in the blood of patients with SLE: Size, content of mitochondria and role in circulating immune complexes. *Journal of Autoimmunity*, **2019**, 102, 142-149	15.5	24
111	High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. *Arthritis Research and Therapy*, **2019**, 21, 107	5.7	50

110	EULAR recommendations for the management of antiphospholipid syndrome in adults. *Annals of the Rheumatic Diseases*, **2019**, 78, 1296-1304	2.4	312
109	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2019**, 78, 736-745	2.4	628
108	Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients-immune-related candidate proteins affected by TNF blocking treatment. *Arthritis Research and Therapy*, **2019**, 21, 60	5.7	6
107	Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. *Journal of Proteome Research*, **2019**, 18, 1208-1217	5.6	9
106	Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study. *Scandinavian Journal of Rheumatology*, **2019**, 48, 141-148	1.9	7
105	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 16955-16960	11.5	53
104	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2019**, 78, 1363-1370	2.4	32
103	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. *Autoimmunity Reviews*, **2019**, 18, 102401	13.6	5
102	Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives. *Arthritis Research and Therapy* , **2019**, 21, 62	5.7	15
101	FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS **2019**,		3
100	Sex differences in clinical presentation of systemic lupus erythematosus. *Biology of Sex Differences*, **2019**, 10, 60	9.3	15
99	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. *European Journal of Human Genetics*, **2019**, 27, 432-441	5.3	10
98	Antiphospholipid Antibodies in Patients With Myocardial Infarction. *Annals of Internal Medicine*, **2019**, 170, 277-280	8	8
97	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2018**, 77, 1063-1069	2.4	21
96	Cardiovascular disease in systemic lupus erythematosus is associated with increased levels of biomarkers reflecting receptor-activated apoptosis. *Atherosclerosis*, **2018**, 270, 1-7	3.1	18
95	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2018**, 77, 736-743	2.4	76
94	Microparticles as autoantigens in systemic lupus erythematosus. *European Journal of Clinical Investigation*, **2018**, 48, e13010	4.6	27
93	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. *Arthritis Research and Therapy*, **2018**, 20, 36	5.7	9

92	Dr. Rossides, reply. *Journal of Rheumatology*, **2018**, 45, 1070	4.1	1
91	TNF-and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. *Lupus Science and Medicine*, **2018**, 5, e000260	4.6	38
90	Response to: Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself? by Bruzzese and Zullo. *Annals of the Rheumatic Diseases*, **2018**, 77, e72	2.4	
89	Obstetric antiphospholipid syndrome. *Lupus Science and Medicine*, **2018**, 5, e000197	4.6	25
88	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. *Clinical and Experimental Immunology*, **2018**, 194, 27-38	6.2	9
87	Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. *Lupus Science and Medicine*, **2018**, 5, e000254	4.6	33
86	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. *Lupus*, **2018**, 27, 1470-1478	2.6	16
85	EULAR recommendations for women health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Annals of the Rheumatic Diseases*, **2017**, 76, 476-485	2.4	375
84	Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 1272-1279	9.5	20
83	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. *Annals of the Rheumatic Diseases*, **2017**, 76, 1544-1549	2.4	61
82	Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. *Lupus*, **2017**, 26, 1023-1033	2.6	24
81	A single nucleotide polymorphism in the gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2017**, 76, 1607-1613	2.4	65
80	Self-reported physical capacity and activity in patients with systemic sclerosis and matched controls. *Scandinavian Journal of Rheumatology*, **2017**, 46, 490-495	1.9	8
79	A comparison of patients and physicians assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. *Scandinavian Journal of Rheumatology*, **2017**, 46, 474-483	1.9	5
78	Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. *Scandinavian Journal of Rheumatology*, **2017**, 46, 263-272	1.9	9
77	Early-onset Preeclampsia in Lupus Pregnancy. *Paediatric and Perinatal Epidemiology*, **2017**, 31, 29-36	2.7	25
76	Depressed serum IgM levels in SLE are restricted to defined subgroups. *Clinical Immunology*, **2017**, 183, 304-315	9	15
75	Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. *PLoS ONE*, **2017**, 12, e0174572	3.7	66

74	Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics. *Metabolomics*, **2017**, 13, 114	4.7	9
73	Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2017**, 44, 1590-1596	4.1	9
72	Transancestral mapping and genetic load in systemic lupus erythematosus. *Nature Communications*, **2017**, 8, 16021	17.4	171
71	Altered β-glycoprotein 1 expression on microparticles in the presence of antiphospholipid antibodies. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1799-1806	15.4	10
70	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. *Scientific Reports*, **2017**, 7, 6236	4.9	31
69	IFN-γ with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). *Arthritis Research and Therapy*, **2017**, 19, 139	5.7	37
68	Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS). *Thrombosis Research*, **2017**, 158, 168-173	8.2	8
67	Troponin I and echocardiography in patients with systemic sclerosis and matched population controls. *Scandinavian Journal of Rheumatology*, **2017**, 46, 226-235	1.9	16
66	Ofatumumab treatment in lupus nephritis patients. *CKJ: Clinical Kidney Journal*, **2016**, 9, 552-5	4.5	29
65	Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. *Scientific Reports*, **2016**, 6, 36025	4.9	51
64	OP0171 Prognosis of Stroke Patients with Systemic Lupus Erythematosus: A Population-Based Cohort Study. *Annals of the Rheumatic Diseases*, **2016**, 75, 120.2-120	2.4	
63	A6.15 Characterisation of systemic lupus erythematosus subgroups with features of antiphospholipid or sjögrens's syndrome utilising affinity proteomics. *Annals of the Rheumatic Diseases*, **2016**, 75, A53.2-A53	2.4	
62	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. *Seminars in Arthritis and Rheumatism*, **2016**, 45, 684-90	5.3	12
61	Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. *Circulation*, **2016**, 133, 576-83	16.7	120
60	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. *Autoimmunity Reviews*, **2016**, 15, 203-9	13.6	32
59	Antiphospholipid Antibodies in Lupus Nephritis. *PLoS ONE*, **2016**, 11, e0158076	3.7	19
58	OP0160 Characterization of Systemic Lupus Erythematosus Subgroups with Features of Antiphospholipid or Sjögrens's Syndrome Utilizing Affinity Proteomics. *Annals of the Rheumatic Diseases*, **2016**, 75, 116.2-116	2.4	
57	Case definitions in Swedish register data to identify systemic lupus erythematosus. *BMJ Open*, **2016**, 6, e007769	3	24

56	Platelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2016**, 68, 1970-80	9.5	46
55	Interferon (IFN)- is a potential mediator in lupus nephritis. *Lupus Science and Medicine*, **2016**, 3, e000170	4.6	36
54	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE. *Arthritis Care and Research*, **2016**, 68, 988-94	4.7	42
53	Lifestyle habits and fatigue among people with systemic lupus erythematosus and matched population controls. *Lupus*, **2015**, 24, 955-65	2.6	21
52	Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. *Lupus Science and Medicine*, **2015**, 2, e000061	4.6	22
51	Prevention of cardiovascular disease in rheumatoid arthritis. *Autoimmunity Reviews*, **2015**, 14, 952-69	13.6	57
50	Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. *Clinical and Experimental Immunology*, **2015**, 181, 417-26	6.2	20
49	Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. *Arthritis Research and Therapy*, **2015**, 17, 109	5.7	23
48	Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. *Annals of the Rheumatic Diseases*, **2015**, 74, 1537-43	2.4	49
47	SAT0401 Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome. *Annals of the Rheumatic Diseases*, **2015**, 74, 804.2-804	2.4	
46	Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis. *Scandinavian Journal of Immunology*, **2015**, 82, 269-74	3.4	16
45	Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. *Autoimmunity*, **2014**, 47, 67-76	3	43
44	THU0530 Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response. *Annals of the Rheumatic Diseases*, **2014**, 73, 366.3-366	2.4	
43	FRI0172 Utility of Swedish Register Data in Classifying Systemic Lupus. *Annals of the Rheumatic Diseases*, **2014**, 73, 444.2-444	2.4	
42	AB0487 Decreased SLE Disease Activity and Corticosteroid Usage and NO Renal Flares during Belimumab Treatment. *Annals of the Rheumatic Diseases*, **2014**, 73, 968.2-968	2.4	1
41	THU0520 Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 363.1-363	2.4	
40	Systemic lupus erythematosus prevalence in Sweden in 2010: what do national registers say?. *Arthritis Care and Research*, **2014**, 66, 1710-7	4.7	24
39	Role of early repeated renal biopsies in lupus nephritis. *Lupus Science and Medicine*, **2014**, 1, e000018	4.6	66

38	Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. *Thrombosis Research*, **2014**, 133, 936-44	8.2	21
37	Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. *Rheumatology*, **2013**, 52, 501-9	3.9	38
36	Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. *Circulation: Cardiovascular Genetics*, **2013**, 6, 255-63		32
35	HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2013**, 72, 1018-25	2.4	40
34	AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus. *Annals of the Rheumatic Diseases*, **2013**, 71, 678.7-678	2.4	
33	A10.23 Stratification of SLE Patients for Improved Diagnosis and Treatment. *Annals of the Rheumatic Diseases*, **2013**, 72, A80.2-A80	2.4	
32	FRI0271 Stratification of sle patients for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2013**, 72, A466.1-A466	2.4	
31	SAT0181 Systems biology of SLE: Biochemical characterization of subgroups within SLE for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2013**, 71, 532.3-532	2.4	
30	THU0162 Thrombotic microangiopathy in renal biopsies from patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2013**, 71, 210.2-210	2.4	
29	THU0309 Coronary Heart Disease in Systemic Lupus Erythematosus is Associated with Interferon Regulatory Factor 8 Gene Variants. *Annals of the Rheumatic Diseases*, **2013**, 72, A270.2-A270	2.4	
28	A research study of the association between maternal microchimerism and systemic lupus erythematosus in adults: a comparison between patients and healthy controls based on single-nucleotide polymorphism using quantitative real-time PCR. *PLoS ONE*, **2013**, 8, e74534	3.7	9
27	Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. *PLoS ONE*, **2013**, 8, e84450	3.7	62
26	Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. *Arthritis Research and Therapy*, **2012**, 14, R46	5.7	106
25	Studies of microparticles in patients with the antiphospholipid syndrome (APS). *Lupus*, **2012**, 21, 802-5	2.6	37
24	Ischemic vascular disease and antiphospholipid antibodies are associated with HLA-DRB1 *04/*13 alleles in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2012**, 71, A57.3-A58	2.4	
23	Systems biology of SLE: biochemical characterisation of subgroups within sle for improved diagnosis and treatment. *Annals of the Rheumatic Diseases*, **2012**, 71, A12.2-A12	2.4	
22	Autoantibodies to the functionally active RING-domain of Ro52/SSA associate with clinical activity in a subset of patients with lupus. *Annals of the Rheumatic Diseases*, **2012**, 71, A40.1-A40	2.4	
21	Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. *Scandinavian Journal of Rheumatology*, **2011**, 40, 363-72	1.9	16

20	Genetic risk factors in lupus nephritis and IgA nephropathy--no support of an overlap. *PLoS ONE*, **2010**, 5, e10559	3.7	20
19	A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2010**, 69, 834-40	2.4	60
18	Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. *Arthritis Research and Therapy*, **2009**, 11, R186	5.7	115
17	Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE). *PLoS ONE*, **2009**, 4, e8037	3.7	12
16	Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. *Scandinavian Journal of Rheumatology*, **2008**, 37, 352-9	1.9	34
15	A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. *Human Molecular Genetics*, **2008**, 17, 2868-76	5.6	164
14	Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease. *Arthritis Research*, **2005**, 7, P105		78
13	Endothelial function and activation in women with systemic lupus erythematosus. *Arthritis Research* , **2005**, 7, P148		78
12	Decreased binding of annexin V to endothelial cells: a novel mechanism of atherothrombosis in patients with systemic lupus erythematosus. *Arthritis Research*, **2005**, 7, P143		78
11	Non-traditional risk and protective factors for cardiovascular disease in systemic lupus erythematosus. *Arthritis Research*, **2005**, 7, P122		78
10	Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. *Arthritis and Rheumatism*, **2005**, 52, 192-200		180
9	Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 198-203	9.4	74
8	Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. *Arthritis and Rheumatism*, **2004**, 50, 2869-76		31
7	The A-1087IL-10 allele is associated with cardiovascular disease in SLE. *Atherosclerosis*, **2004**, 177, 409-14	3.1	25
6	Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. *Arthritis and Rheumatism*, **2003**, 48, 2533-40		116
5	TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. *Lupus*, **2003**, 12, 454-61	2.6	113
4	Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. *Lupus*, **2002**, 11, 744-52	2.6	23
3	Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. *Annals of the Rheumatic Diseases*, **2001**, 60, 372-9	2.4	74

2	Risk factors for cardiovascular disease in systemic lupus erythematosus. *Circulation*, **2001**, 104, 1887-93	16.7	397
1	Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. *American Journal of Medicine*, **1998**, 104, 332-8	2.4	414